trending Market Intelligence /marketintelligence/en/news-insights/trending/4JENKPjQIqeV1oB-WNdSyA2 content esgSubNav
In This List

Dova Pharmaceuticals appoints president/CEO, chief commercial officer

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Dova Pharmaceuticals appoints president/CEO, chief commercial officer

Dova Pharmaceuticals Inc. appointed David Zaccardelli president and CEO, and also named Jason Hoitt chief commercial officer.

Zaccardelli — who was previously acting CEO of Cempra Pharmaceuticals Inc. until the company's merger with Melinta Therapeutics Inc. — is replacing Alex Sapir in the president and CEO roles.

Hoitt was previously vice president and head of U.S. sales at Insmed Inc. and head of U.S. sales and senior director of medical affairs at Sarepta Therapeutics Inc.

Dova expects the appointments of Zaccardelli and Hoitt to accelerate the launch of the company's bleeding disorder drug Doptelet. The therapy was approved by the U.S. Food and Drug Administration in May to treat thrombocytopenia, a condition characterized by an abnormally low platelet count, in adults with chronic liver disease.

Dova is also seeking the U.S. FDA's approval for Doptelet as a therapy for immune thrombocytopenia, a bleeding disorder that can lead to excessive bruising and bleeding due to low levels of platelets in the blood.